178 related articles for article (PubMed ID: 1672872)
21. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
22. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.
Tavassoli M; Quirke P; Farzaneh F; Lock NJ; Mayne LV; Kirkham N
Br J Cancer; 1989 Oct; 60(4):505-10. PubMed ID: 2572268
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma--a detailed morphological analysis.
Ramachandra S; Machin L; Ashley S; Monaghan P; Gusterson BA
J Pathol; 1990 May; 161(1):7-14. PubMed ID: 1973459
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.
Bartkova J; Barnes DM; Millis RR; Gullick WJ
Hum Pathol; 1990 Nov; 21(11):1164-7. PubMed ID: 1977679
[TBL] [Abstract][Full Text] [Related]
25. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
[TBL] [Abstract][Full Text] [Related]
26. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ.
Barnes DM; Meyer JS; Gonzalez JG; Gullick WJ; Millis RR
Breast Cancer Res Treat; 1991 Mar; 18(1):11-7. PubMed ID: 1677296
[TBL] [Abstract][Full Text] [Related]
27. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas.
Satoh K; Sasano H; Shimosegawa T; Koizumi M; Yamazaki T; Mochizuki F; Kobayashi N; Okano T; Toyota T; Sawai T
Cancer; 1993 Jul; 72(1):51-6. PubMed ID: 8099533
[TBL] [Abstract][Full Text] [Related]
28. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
Buttitta F; Felicioni L; Barassi F; Martella C; Paolizzi D; Fresu G; Salvatore S; Cuccurullo F; Mezzetti A; Campani D; Marchetti A
J Pathol; 2006 Feb; 208(3):350-5. PubMed ID: 16353168
[TBL] [Abstract][Full Text] [Related]
30. c-erbB-2 expression in breast cancer detected by immunoblotting and immunohistochemistry.
Kerns BJ; Pence JC; Huper G; Kinney RB; Iglehart JD
J Histochem Cytochem; 1990 Dec; 38(12):1823-30. PubMed ID: 1979342
[TBL] [Abstract][Full Text] [Related]
31. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
[TBL] [Abstract][Full Text] [Related]
32. [C-erbB-2 oncogene amplification in breast cancer in correlation to steroid and epidermal growth factor receptor].
Manavi M; Czerwenka KF; Zeillinger R; Speiser P; Kury F; Steinhart U; Peschke M; Kubista E; Reinold E
Zentralbl Gynakol; 1992; 114(2):82-5. PubMed ID: 1350129
[TBL] [Abstract][Full Text] [Related]
33. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
Naidu R; Wahab NA; Yadav M; Kutty MK
Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
[TBL] [Abstract][Full Text] [Related]
34. [Her-2 amplification and p185 expression in invasive breast cancer cells in women].
Titi S
Ann Acad Med Stetin; 2006; 52(2):5-12. PubMed ID: 17633393
[TBL] [Abstract][Full Text] [Related]
35. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma.
Martinazzi M; Crivelli F; Zampatti C; Martinazzi S
J Clin Pathol; 1993 Nov; 46(11):1009-10. PubMed ID: 8254086
[TBL] [Abstract][Full Text] [Related]
37. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
38. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
Walker RA; Dearing SJ; Lane DP; Varley JM
J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers.
Kobayashi S; Iwase H; Itoh Y; Fukuoka H; Yamashita H; Kuzushima T; Iwata H; Masaoka A; Kimura N
Jpn J Cancer Res; 1992 Aug; 83(8):859-65. PubMed ID: 1356959
[TBL] [Abstract][Full Text] [Related]
40. Keratin 19 in paraffin sections of medullary carcinoma and other benign and malignant breast lesions.
Dalal P; Shousha S
Mod Pathol; 1995 May; 8(4):413-6. PubMed ID: 7567941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
